,
, A cette solution, on ajoute la benzylamine (4,33 mL, 39,7 mmol) ainsi que la TEA (14,5 mL, 104 mmol). Le mélange est chauffé au reflux du n-BuOH pendant 3 heure. Par filtration sous vide puis rinçage au n-BuOH froid (2 x 10 mL), le produit 1 est récupéré sous forme de poudre blanche, On dissout la 2,6-dichloro-9H-purine (5 g, 26 mmol) dans le n-BuOH (40mL), vol.46
, Masse molaire : 259,69 g / mol Aspect : poudre blanche Rdt moyen : 96 %
, DMSO-d6): ? 4.63 (d, 2H, J = 5.2 Hz, CH2-NH), vol.7
CH2); pour : -5 g de 2,6-dichloro-9H-purine : Rdt = 92 % -15 g de 2,6-dichloro-9H-purine : Rdt = 98 % -15 g de 2,6-dichloro-9H-purine : Rdt = 96, vol.2 ,
, g / mol Aspect : poudre blanche hygroscopique Point de fusion, p.62
, CH3-CH2-CH,); 0.80 (d, 6H, J = 6.8 Hz, (CH3)2-CH-CH,); 1.40 (s, 6H, (CH3)2-CH-NH), RMN 1 H (DMSO-d6): ? 0.75 (d, 3H, J = 6.4 Hz, vol.1
DMSO-d6): ? 17.68, vol.18, p.50 ,
g de (S)-CR8 et 0,591 g de Val Chloro Phosphorochloridate pour obtenir 0,027 g de CR8 Val H, vol.25 ,
, BIBLIOGRAPHIE
CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD ,
, Cell Cycle, vol.11, issue.21, pp.4040-4046, 2012.
Normal Values for Renal Length and Volume as Measured by Magnetic Resonance Imaging, Clin. J. Am. Soc. Nephrol, vol.2, pp.38-45, 2007. ,
, , vol.3, 2017.
, Connaître la polykystose
,
, Département de médecine, service de néphrologie
, Le système Rénine-Angiotensine-Aldostérone, 2018.
,
, Site du, 2018.
,
Le diagnostic de PKD ,
,
Université Paris Descartes, Site de l'INSERM ,
,
Polykystose rénale. Ellipses, éditeur. Réussir l'ECN, 7 ème édition, pp.267-277, 2016. ,
JINARC (tolvaptan), antagoniste de la vasopressine ,
,
JINARC (tolvaptan) : premier médicament dans la prise en charge de la PKRAD ,
,
,
,
Marcus wins chemistry Nobel. Two biochemists take medicine prize, Chem. Eng. News, vol.70, pp.6-7, 1992. ,
,
, Mémoire sur la diastase, les principaux produits de ses réactions et leurs applications aux arts industriels, Annales de chimie, pp.73-92
,
, The protein kinase complement of the human genome
, Science, vol.298, pp.1912-1946, 2002.
, The nobel prize in physiology or medicine, 2001.
,
The cell cycle : a review of regulation, deregulation and therapeutic targets in cancer, Cell Cycle, vol.36, pp.131-180, 2003. ,
, Therapeutics in Renal Disease : The Road Ahead for Antiproliferative Targets, vol.1, pp.6-15, 2006.
Alzheimer's disease ?, Biochim. Biophys. Acta, vol.1697, pp.137-179, 2004. ,
Le cancer : nouvelles données, nouvelles stratégies, nouveaux espoirs. ; 18 mars, vol.8, pp.53-58, 2004. ,
,
, A minute chromosom in human chronic granulocytic leukemia. Nowell P.C. ; Hungerford D. ; Science, 142, p.1497, 1960.
,
, J. Cancer, vol.38, issue.suppl5, pp.28-36, 2002.
, STI571 : a New Treatment Modality on CML ?, pp.245-259, 2001.
, La résistance à l'imatinib dans la leucémie myéloïde chronique : Etude des mécanismes moléculaires. Pocaly, M. ; Thèse pour le Doctorat de l'Université de Bordeaux 2, p.1486, 2007.
, Résistance à l'imatinib mésylate par mutation Bcr-Abl au cours de la leucémie myéloïde chronique, vol.13, pp.457-464, 2007.
, Nature reviews Drug Discovery, vol.5, pp.279-280, 2006.
, Nilotinib : a novel, selective tyrosine kinase inhibitor, Semin. Oncol, p.467, 2011.
, Nature reviews Drug Discovery, vol.5, pp.717-718, 2006.
Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5, Eur. J. Med. chem, vol.243, pp.527-563, 1997. ,
Roscovitine and others purines as kinase inhibitors. From starfish oocytes to clinical trials, Acc. Chem. Res, vol.36, issue.6, pp.417-442, 2003. ,
Anticancer Drug Development, 2001. ,
, , 2005.
,
, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
Advanced drug delivery reviews, vol.23, pp.3-25, 1997. ,
Cytokinin-derived cyclin-dependent kinase inhibitors : synthesis and cdc2 inhibitory activity of olomoucine and related compounds ,
, J. Med. Chem, vol.40, pp.408-412, 1997.
, Tyrosine kinase inhibitors : from rational design to clinical trials, vol.21, pp.499-512, 2001.
, Roscovitine targets, protein kinases and pyridoxal kinase
,
, J. Biol. Chem, vol.280, pp.31208-31227, 2005.
, Expert Opinion on Investigational Drugs, vol.18, issue.2, 2009.
Roscovitine-derived, dual specificity inhibitors of cyclin-dependent kinases and casein kinases 1 ,
URL : https://hal.archives-ouvertes.fr/hal-00319796
, J. Med. Chem, vol.51, pp.5229-5271, 2008.
CR8, a potent and selective, roscovitine-derived inhibitor of cyclindependent kinases, Oncogene, vol.27, pp.5797-5807, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-00319794
,
,
, Human Molecular Genetics, vol.25, issue.11, pp.2245-2255, 2016.
, The therapeutic Potential of Candoxatril, a Neutral Endopeptidase Inhibitor, Cardiovascular Drug Review, vol.18, issue.4, pp.259-270, 2000.
A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infection, Perry C.M., Faulds D, vol.52, pp.754-72, 1996. ,
, Pharmacokinetics of amipicillin and its prodrugs bacampicillin and pivampicillin in man, vol.7, pp.429-51, 1979.
Cell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy, J. Am. Chem. Soc, vol.133, pp.16680-16688, 2011. ,
, Mechanism-Based Tumor-Targeting Drug Delivery System. Validation of Efficient Vitamin Receptor-Mediated Endocytosis and Drug Release
, Bioconjug. Chem, vol.21, pp.979-87, 2010.
Metabolism, Pharmacokinetics, and Toxicity of Functional Groups : Impact of the Building Blocks of Medicinal Chemistry in ADMET ,
Activation of the anticancer prodrugs cyclophosphamide and ifosfamide : identification of cytochrome P4520 2B enzyme and site-specific mutants with improved enzyme kinetics, Mol. Pharmacol, vol.65, pp.1278-85, 2004. ,
, Studies on the mechanism of absorption of depot neuroleptics : fluphenazinedecanoate in sesame oil, Pharm. Res, vol.14, pp.1079-84, 1997.
The Organic Chemistry of Drug Design and Drug Action, 2014. ,
Application of Phosphoramidate Pronucleotide Technology to Abcavir Leads to a Significant Enhancement of Antiviral Potency, J. Med. Chem, vol.48, pp.3504-3515, 2005. ,
Phosphoramidate ProTides of the Anticancer Agent FUDR Successfully Deliver the Preformed Bioactive Monophosphate in Cells and Confer Advantage over the Parent Nucleoside, J. Med. Chem, vol.54, pp.7247-7258, 2011. ,
, Application of ProTide Technology to Gemcitabine : A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC1031) in Clinical Development
, J. Med. Chem, vol.57, pp.1531-1542, 2014.
, Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides
, Eur. J. Med. Chem, vol.70, pp.326-340, 2013.